VELCADE 3.5 mg/1 viala prašak za rastvor za injekciju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

velcade 3.5 mg/1 viala prašak za rastvor za injekciju

inpharm co. d.o.o. banja luka - bortezomib - prašak za rastvor za injekciju - 3.5 mg/1 viala - 1 bočica sa praškom za otopinu za injekciju sadrži: 3,5 mg bortezomib

Imbruvica Europska Unija - hrvatski - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Bendamustin Kabi 2,5 mg/ml prašak za koncentrat za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bendamustin kabi 2,5 mg/ml prašak za koncentrat za otopinu za infuziju

fresenius kabi d.o.o., radnička cesta 37a, zagreb, hrvatska - bendamustinklorid - prašak za koncentrat za otopinu za infuziju - 2,5 mg/ml - urbroj: jedna bočica sadrži 25 mg bendamustinklorida; jedna bočica sadrži 100 mg bendamustinklorida; nakon rekonstitucije 1 ml koncentrata sadrži 2,5 mg bendamustinklorida

Bendamustin PharmaS 2,5 mg/ml prašak za koncentrat za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bendamustin pharmas 2,5 mg/ml prašak za koncentrat za otopinu za infuziju

pharmas d.o.o., radnička cesta 47, zagreb, hrvatska - bendamustinklorid hidrat - prašak za koncentrat za otopinu za infuziju - 2,5 mg/ml - urbroj: jedna bočica sadrži 25 mg bendamustinklorida (u obliku bendamustinklorid hidrata) jedna bočica sadrži 100 mg bendamustinklorida (u obliku bendamustinklorid hidrata) nakon rekonstitucije 1 ml koncentrata sadrži 2,5 mg bendamustinklorida

STINDAB 25 mg/1 bočica prašak za koncentrat za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

stindab 25 mg/1 bočica prašak za koncentrat za rastvor za infuziju

sandoz d.o.o. - bendamustin - prašak za koncentrat za rastvor za infuziju - 25 mg/1 bočica - 1 bočica sadrži: 25 mg bendamustin hidrohlorida

STINDAB 100 mg/1 bočica prašak za koncentrat za rastvor za infuziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

stindab 100 mg/1 bočica prašak za koncentrat za rastvor za infuziju

sandoz d.o.o. - bendamustin - prašak za koncentrat za rastvor za infuziju - 100 mg/1 bočica - 1 bočica sadrži: 100 mg bendamustin hidrohlorida

Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) Europska Unija - hrvatski - EMA (European Medicines Agency)

lenalidomide krka d.d. novo mesto (previously lenalidomide krka)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - imunosupresivi - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) indiciran za liječenje odraslih bolesnika s ranije нелеченной multiplog mijeloma koji se ne oslanja transplantacije. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) indiciran za liječenje odraslih bolesnika s ranije нелеченной multiplog mijeloma koji se ne oslanja transplantacije. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Bendamustin Teva 2,5 mg/ml prašak za koncentrat za otopinu za infuziju Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

bendamustin teva 2,5 mg/ml prašak za koncentrat za otopinu za infuziju

teva b.v., swensweg 5, haarlem, nizozemska - bendamustinklorid - prašak za koncentrat za otopinu za infuziju - 2,5 mg/ml - urbroj: 1 ml koncentrata sadrži 2,5 mg bendamustinklorid nakon rekonstitucije jedna bočica od 26 ml sadrži 25 mg bendamustinklorida jedna bočica od 60 ml sadrži 100 mg bendamustinklorida

Lenalidomide Accord Europska Unija - hrvatski - EMA (European Medicines Agency)

lenalidomide accord

accord healthcare s.l.u. - lenalidomid - multipli mijelom - imunosupresivi - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) indiciran za liječenje odraslih bolesnika s ranije нелеченной multiplog mijeloma koji se ne oslanja transplantacije. akord леналидомид u kombinaciji s дексаметазоном indiciran za liječenje multiple myeloma kod odraslih pacijenata koji su primili barem jedan tečaj terapija. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Lenalidomide Mylan Europska Unija - hrvatski - EMA (European Medicines Agency)

lenalidomide mylan

mylan ireland limited - lenalidomid - multipli mijelom - imunosupresivi - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).